Molecule
|
Dose (i.v.)mg/kg
|
Isotype
|
Cmax(μg/ml)
|
AUClast(μg/ml day)
|
CLobs(ml/day/kg)
|
Biacore monomericAβ Kd (nM)
|
Biacore oligomericAβ Kd (nM)
|
---|
Crenezumab
|
20
|
hIgG4
|
296
|
882
|
19.6
|
5
|
0.5
|
Anti-moAβ [23]
|
20
|
hIgG1
|
319
|
113
|
176.4
|
0.2
|
Not detected
|
Anti-gD
|
20
|
hIgG1
|
410
|
1457
|
7.6
|
–
|
–
|
- PK pharmacokinetics, i.v. intravenous, Cmax maximum concentration, AUClast area under the curve from the time of last dosing to the last measurable concentration, CLobs total body clearance, Aβ amyloid β, hIgG humanized immunoglobulin G, moAβ monomeric amyloid β, gD glycoprotein D